Donna Masterman
About Donna Masterman
Donna Masterman serves as the VP of Medical Affairs and Neuroscience Lead at Prothena Corporation plc, specializing in neurology and neurotherapeutics. With extensive experience in the pharmaceutical industry, she has held key positions at Genentech, Biogen, Amgen, and Roche, focusing on Alzheimer's disease research and treatment pathways.
Current Role at Prothena
Donna Masterman serves as the Vice President of Medical Affairs and Neuroscience Lead at Prothena Corporation plc. She has held this position since 2022, contributing her expertise in neurology and neurotherapeutics. Based in the San Francisco Bay Area, she focuses on advancing the company's initiatives in neuroscience.
Previous Experience at Biogen
Prior to her current role, Donna Masterman worked at Biogen from 2018 to 2022. During her tenure, she held multiple positions, including Executive Medical Director and Global Medical, AD Head for the Biogen Intercontinental Region. Her work involved leadership in Alzheimer’s disease and movement disorders, significantly impacting the company's medical strategy.
Experience at Genentech and Roche
Donna Masterman spent 11 years at Genentech from 2007 to 2018, where she served as Associate Group Medical Director and Principal Medical Director. Additionally, she worked at Roche as Senior Medical Director and Clinical Science Leader from 2010 to 2013. These roles contributed to her extensive background in medical affairs and clinical science.
Educational Background and Specialization
Donna Masterman studied at the University of Washington, where she earned her Doctor of Medicine (MD) and a Master of Science (M.S.) in Physiology and Biophysics from 1983 to 1989. She also completed fellowship training in Neuropsychiatry/Neurobehavior and Movement Disorders, specializing in neurology and neurotherapeutics.
Research Focus and Publications
Donna Masterman has a strong focus on Alzheimer's disease research and treatment pathways. She has authored an OpEd discussing the future of Alzheimer's disease research, contributing to the dialogue on advancements in this critical area of medicine.